Phase I study of intraarterial ONYX-15 [lontucirev] in combination with intravenous cisplatin and fluorouracil in patients with advanced squamous cell cancer of the head and neck
Latest Information Update: 08 Jul 2013
At a glance
- Drugs Lontucirev (Primary) ; Cisplatin; Fluorouracil
- Indications Head and neck cancer
- Focus Adverse reactions
- 29 Sep 2006 Status change
- 05 Aug 2005 New trial record.